# ScoreItem: Doença renal crônica

**ID:** `019bf31d-2ef0-7adb-8bd5-a242485e0446`
**FullName:** Doença renal crônica (Histórico de doenças - Doenças crônicas (Questionar ativamente as doenças crônicas mais comuns, perguntar sobre duração, grau de controle e tratamentos utilizados no passado e atualmente))

**Preparation Metadata:**
- Quality Grade: **GOOD**
- Total Chunks: 30 de 5 artigos
- Avg Similarity: 0.569

---

## Contexto

Você é um especialista em medicina funcional integrativa e está contribuindo com o **Escore Plenya** — um escore completo de análise de saúde que avalia todos os aspectos da saúde, performance e longevidade humana. Cada ScoreItem representa um parâmetro clínico, laboratorial, genético, comportamental ou histórico que compõe esse escore.

Seu papel é gerar conteúdo clínico de alta qualidade para enriquecer cada parâmetro do escore com relevância clínica, orientação ao paciente e conduta prática.

**Regras inegociáveis:**
- Use **apenas** o conhecimento médico real consolidado e os dados presentes nos chunks científicos abaixo
- **Não alucine, não invente** dados, estudos, estatísticas ou referências que não estejam nos chunks ou no seu conhecimento médico estabelecido
- Se um dado específico não constar nos chunks e não for do seu conhecimento consolidado, **não o inclua**
- Seja preciso: prefira omitir a inventar

## Instrução

Com base nos chunks científicos abaixo, gere as respostas em formato JSON.

**O JSON deve obrigatoriamente conter o campo `score_item_id` com o valor `019bf31d-2ef0-7adb-8bd5-a242485e0446`.**

```json
{
  "score_item_id": "019bf31d-2ef0-7adb-8bd5-a242485e0446",
  "clinical_relevance": "Texto técnico para médicos (1000-5000 chars): definição fisiológica precisa, valores de referência e interpretação, fisiopatologia resumida, dados epidemiológicos com números concretos, estratificação de risco baseada em evidências.",
  "points": 1,
  "patient_explanation": "Texto simples para pacientes (500-1000 chars): o que é este parâmetro sem jargões, por que é importante para a saúde, o que valores alterados podem significar. Tom tranquilizador e educativo.",
  "conduct": "Conduta clínica em Markdown (1000-5000 chars): investigação complementar necessária, critérios de encaminhamento a especialistas, intervenções baseadas em evidências. Use bullet points, seções e negrito."
}
```

**Regras para `points` (1-50):**
- Baixo impacto clínico: 1-9 pts
- Alto impacto clínico: 10-19 pts
- Alto impacto em mortalidade: 20-50 pts
- Critérios: gravidade/mortalidade (40%), prevalência (30%), intervencionabilidade (30%)

---

### Contexto Científico

**ScoreItem:** Doença renal crônica (Histórico de doenças - Doenças crônicas (Questionar ativamente as doenças crônicas mais comuns, perguntar sobre duração, grau de controle e tratamentos utilizados no passado e atualmente))

**30 chunks de 5 artigos (avg similarity: 0.569)**

### Chunk 1/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.624

arltrationrate[eGFRcr-cys])(1B).1.1.3EvaluationofchronicityPracticePoint1.1.3.1:Proofofchronicity(durationofaminimumof3months)canbeestablishedby:(i)reviewofpastmeasurements/estimationsofGFR;(ii)reviewofpastmeasurementsofalbuminuriaorproteinuriaandurinemicroscopicexaminations;(iii)imagingndingssuchasreducedkidneysizeandreductionincorticalthickness;(iv)kidneypathologicalndingssuchasbrosisandatrophy;(v)medicalhistory,especiallyconditionsknowntocauseorcontributetoCKD;(vi)repeatmeasurementswithinandbeyondthe3-monthpoint.PracticePoint1.1.3.2:DonotassumechronicitybaseduponasingleabnormallevelforeGFRandACR,asthendingcouldbetheresultofarecentacutekidneyinjury(AKI)eventoracutekidneydisease(AKD).PracticePoint1.1.3.3:ConsiderinitiationoftreatmentsforCKDatrstpresentationofdecreasedGFRorelevatedACRifCKDisdeemedlikelyduetopresenceofotherclinicalindicators.1.1.4Evaluationofcause
PracticePoint1.1.4.1:EstablishthecauseofCKDusingclinicalcontext,personalandfamilyhistory,socialandenvi-ronmentalfactor

---

### Chunk 2/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** results | **Similarity:** 0.603

e-basedequations.TransplInt.2012;25:527–536.162.JanusN,Launay-VacherV,ByloosE,etal.CancerandrenalinsufciencyresultsoftheBIRMAstudy.BrJCancer.2010;103:1815–1821.163.Launay-VacherV,JanusN,DerayG.Renalinsufciencyandcancertreatments.ESMOOpen.2016;1:e000091.164.NaSY,SungJY,ChangJH,etal.Chronickidneydiseaseincancerpatients:anindependentpredictorofcancer-specicmortality.AmJNephrol.2011;33:121–130.165.RosnerMH,JhaveriKD,McMahonBA,etal.Onconephrology:the
intersectionsbetweenthekidneyandcancer.CACancerJClin.2021;71:47–77.166.SoveriI,BergUB,BjorkJ,etal.MeasuringGFR:asystematicreview.AmJKidneyDis.2014;64:411–424.167.WhiteCA,AkbariA,AllenC,etal.Simultaneousglomerularltrationratedeterminationusinginulin,iohexol,and99mTc-DTPAdemonstratestheneedforcustomizedmeasurementprotocols.KidneyInt.2021;99:957–966.168.XieP,HuangJM,LiuXM,etal.(99m)Tc-DTPArenaldynamicimaging
methodmaybeunsuitabletobeusedasthereferencemethodin
investigatingthevalidityofCDK-EPIequationfordetermining
glomerularltrati

---

### Chunk 3/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** results | **Similarity:** 0.599

eknowledgegainedmoreeffec-
tively.793–797PracticalimplementationtipsinvolveprintingouttheresultsofthemostrecenteGFRestimationforthe
patienttobringalonginfuturehealthcareconsultationsand/
orwritedownalistofongoingmedicationstoalertotherhealthcareprovidersofmedicationrisksandbenets.AdiagnosisofCKDshouldalwaysbereectedinmedicalrecords,asthiswillalertphysiciansontheneedtoconsideradjustingoravoidingcertainmedicationsorprocedures.Under-recognitionofCKDdiagnosesinmedicalrecordsis
associatedwithmedicationerrors,includingpotentially
inappropriateprescriptionofnephrotoxicmedications.729PracticePoint4.3.1.2:Establishcollaborativerelationships
withotherhealthcareprovidersandpharmacistsand/or
usetoolstoensureandimprovedrugstewardshipinpeople
withCKDtoenhancemanagementoftheircomplex
medicationregimens.Clinicalpharmacistsarehighlyqualiedexpertsinmedi-cinesand,aspartofthemultidisciplinaryteam,canplaya
pivotalroleinimprovingthequalityofcareandensuringpatientsafetyinarangeofways.Thisincludescarryin

---

### Chunk 4/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** results | **Similarity:** 0.580

unicatedtopeoplewithCKDanddocumentedinthemedicalrecord.4.3.1StrategiestopromotedrugstewardshipPracticePoint4.3.1.1:EducateandinformpeoplewithCKDregardingtheexpectedbenetsandpossiblerisksofmedicationssothattheycanidentifyandreportadverseeventsthatcanbemanaged.Peoplewithkidneydiseasehavearoleindrugstewardship,andgiventhattheymayreceivemedicationsfromnon-nephrologyhealthcareproviders,peoplewithCKDshouldbe
encouragedtoinformthoseprescribersthattheyhavekidney
diseasetofacilitateconsiderationofdosesandpotentialside
effectofmedications.Thus,educationandinformationfor
peoplewithCKDinclusivefortheirpopulation(i.e.,literacylevelandlanguages)areencouraged.Althoughbrochuresandconversationsmaybeuseful,interactiveelectronichealth
applicationshavebeenshowntobeacceptabletopatientsand
mayleadthemtoapplytheknowledgegainedmoreeffec-
tively.793–797PracticalimplementationtipsinvolveprintingouttheresultsofthemostrecenteGFRestimationforthe
patienttobringalonginfuturehealthcareconsultationsand/
orwritedown

---

### Chunk 5/30
**Article:** Dislipidemias II (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.580

dade, inatividade física, pressão arterial e dislipidemia.
- A inflamação é indicada por marcadores como a Proteína C-Reativa (PCR), onde um valor de 5 já é considerado elevado, e a Interleucina 6 (exemplo de paciente com 8.45).
- A resposta anti-inflamatória é medida pela Interleucina 10, com um valor de corte de 3,5 (abaixo disso é um risco) e um exemplo de paciente com 6.44.
- A saúde do endotélio é avaliada pelo óxido nítrico, que deve estar em 8.8; um paciente com 4.8 já apresenta disfunção sistêmica.
- A LDL oxidada é um marcador crítico, com um limite saudável de 133, enquanto pacientes de alto risco podem apresentar valores extremos, como 1000.
**Achados Adicionais**
- Existem cinco parâmetros clássicos para definir a síndrome metabólica.
- O alvo de LDL para pacientes de alto risco, segundo as diretrizes atuais, é de 50.

---

### Chunk 6/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.579

andthe“new”stagesbetterreecttheirriskassocia-tions.Forthatreason,whereavailable,cystatinCshouldbe
addedtocreatinineforthepurposeofestimatingGFRfor
CKDdiagnosisandstaging.1.1.3EvaluationofchronicityPracticePoint1.1.3.1:Proofofchronicity(durationofa
minimumof3months)canbeestablishedby:(i)reviewofpastmeasurements/estimationsofGFR;(ii)reviewofpastmeasurementsofalbuminuriaor
proteinuriaandurinemicroscopicexaminations;(iii)imagingndingssuchasreducedkidneysizeandreductionincorticalthickness;(iv)kidneypathologicalndingssuchasbrosisandatrophy;(v)medicalhistory,especiallyconditionsknownto
causeorcontributetoCKD;(vi)repeatmeasurementswithinandbeyondthe3-
monthpoint.PracticePoint1.1.3.2:Donotassumechronicitybased
uponasingleabnormallevelforeGFRandACR,asthendingcouldbetheresultofarecentacutekidneyinjury(AKI)eventoracutekidneydisease(AKD).PracticePoint1.1.3.3:ConsiderinitiationoftreatmentsforCKDatrstpresentationofdecreasedGFRorelevatedACRifCKDisdeemedlikelyduetopresenceofotherclinicalindic

---

### Chunk 7/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.578

RifCKDisdeemedlikelyduetopresenceofotherclinicalindicators.1.1.4Evaluationofcause
PracticePoint1.1.4.1:EstablishthecauseofCKDusingclinicalcontext,personalandfamilyhistory,socialandenvi-ronmentalfactors,medications,physicalexamination,laboratorymeasures,imaging,andgeneticandpathologicdiagnosis(Figure8).
www.kidney-international.orgsummaryofrecommendationstatementsandpracticepointsKidneyInternational(2024)105(Suppl4S),S117–S314S149

PracticePoint1.1.4.2:Useteststoestablishacausebasedonresourcesavailable(Table622,98-100).Recommendation1.1.4.1:Wesuggestperformingakidneybiopsyasanacceptable,safe,diagnostictesttoevaluatecauseandguidetreatmentdecisionswhenclinicallyappropriate(2D).1.2EvaluationofGFR1.2.1OtherfunctionsofkidneysbesidesGFR
PracticePoint1.2.1.1:Usetheterm“GFR”whenreferringtothespecickidneyfunctionofglomerularltration.Usethemoregeneralterm“kidneyfunction(s)”whendealingwiththetotalityoffunctionsofthekidney.

---

### Chunk 8/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.577

studies,adoublingoftheACRwithina2-yeardurationisassociatedwithanincreasein
theriskofprogressiontokidneyfailureby50%–100%.391,392
Albuminuria categoriesDescription and rangeGFR categories (ml/min/1.73 m2)Description and rangeA1G1≥90G260–89G3a45–59G3b30–44G415–29G5<15Kidney failureSeverely decreasedModerately toseverely decreasedMildly tomoderately decreasedMildly decreasedNormal or highA2A3Normal to mildlyincreasedModeratelyincreasedSeverelyincreased<30 mg/g<3 mg/mmolScreen1Screen1Treat1Treat1Treat3Treat3Treat1Treat2Treat2Treat3Treat3Treat3Treat*3Treat4+Treat*3Treat4+Treat4+Treat4+30–299 mg/g3–29 mg/mmol≥300 mg/g≥30 mg/mmolCKD is classified based on:�Cause (C)�GFR (G)� Albuminuria (A)Low risk (if no other markers of kidney disease, no CKD)Moderately increased riskHigh risk
Very high risk
Figure13|Frequencyofmonitoringglomerularltrationrate(GFR)andalbuminuriainpeoplewithchronickidneydisease(CKD).AlbuminuriaandGFRgridreectstheriskofprogressionbyintensityofcolor

---

### Chunk 9/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.576

specickidneyfunctionofglomerularltration.Usethemoregeneralterm“kidneyfunction(s)”whendealingwiththetotalityoffunctionsofthekidney.
PhysicalexamNephrotoxicmedicationsSymptoms and signsof urinary tractabnormalitiesSymptoms and signsof systemic diseasesLaboratory tests, imaging, and tissue sample, such as:• Urinalysis and urine sediment• Urine albumin-to-creatinine ratio• Serologic tests
• Ultrasound• Kidney biopsy• Genetic testingMedicalhistorySocial andenvironmentalhistoryObtain careful family historyfor possible genetic causes,including family pedigree for CKD
Figure8|Evaluationofcauseofchronickidneydisease(CKD).

---

### Chunk 10/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.575

romnaturalvariation.Lastly,itshouldbenotedthatrestrictingsaltintake
mayhelpensuremaximaleffectsofRASi.PracticePoint3.6.7:ContinueACEiorARBinpeoplewithCKDevenwhentheeGFRfallsbelow30ml/minper
1.73m2.InarecentSTOP-ACEitrialof411participantswithmeaneGFRof13ml/minper1.73m2,apolicyofdiscontinuingRASiinCKDG4–G5didnotresultinanykidneyorcar-diovascularbenets.507Twoobservationalstudieshavealsofoundthatassociationssuggestingoutcomeswereworse
amongparticipantswhostoppedRASiafterreachingan
www.kidney-international.orgchapter3KidneyInternational(2024)105(Suppl4S),S117–S314S213

eGFR<30ml/minper1.73m2,comparedwiththosewhocontinue.508,509Inaddition,arecentindividualpatientleveldatameta-analysisdemonstratedabenetindelayingKRTinpatientswitheGFR<30ml/minper1.73m2.5103.7Sodium-glucosecotransporter-2inhibitors(SGLT2i)TheWorkGroupconcurswiththeKDIGO2022ClinicalPracticeGuidelineforDiabetesManagementinChronicKidneyDisease,whichstated:“Werecommendtreatingpa-tientswithtype2diabetes(T2D),CKD,andaneGFR$20

---

### Chunk 11/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** methods | **Similarity:** 0.572

ey-international.orgS148KidneyInternational(2024)105(Suppl4S),S117–S314

SummaryofrecommendationstatementsandpracticepointsChapter1:EvaluationofCKD1.1DetectionandevaluationofCKD1.1.1DetectionofCKDPracticePoint1.1.1.1:Testpeopleatriskforandwithchronickidneydisease(CKD)usingbothurinealbuminmea-surementandassessmentofglomerularltrationrate(GFR).PracticePoint1.1.1.2:Followingincidentaldetectionofelevatedurinaryalbumin-to-creatinineratio(ACR),hematuria,orlowestimatedGFR(eGFR),repeatteststoconrmpresenceofCKD.1.1.2MethodsforstagingofCKDRecommendation1.1.2.1:InadultsatriskforCKD,werecommendusingcreatinine-basedestimatedglomer-ularltrationrate(eGFRcr).IfcystatinCisavailable,theGFRcategoryshouldbeestimatedfromthecombinationofcreatinineandcystatinC(creatinineandcystatinC–basedestimatedglomerularltrationrate[eGFRcr-cys])(1B).1.1.3EvaluationofchronicityPracticePoint1.1.3.1:Proofofchronicity(durationofaminimumof3months)canbeestablishedby:(i)reviewofpastmeasurements/estimationsofGFR;(ii)revie

---

### Chunk 12/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** results | **Similarity:** 0.570

adultswithadvancedchronickidneydisease:resultsfromthe
EQUALstudy.JRenNutr.2018;28:165–174.876.LimSL,LinXH,DanielsL.Seven-pointsubjectiveglobalassessmentis
moretimesensitivethanconventionalsubjectiveglobalassessmentin
detectingnutritionchanges.JPENJParenterEnteralNutr.2016;40:966–972.877.GraterolTorresF,MolinaM,Soler-MajoralJ,etal.Evolvingconceptson
inammatorybiomarkersandmalnutritioninchronickidneydisease.Nutrients.2022;14:4297.878.PawlaczykW,RogowskiL,KowalskaJ,etal.Assessmentofthenutritional
statusandqualityoflifeinchronickidneydiseaseandkidneytransplant
patients:acomparativeanalysis.Nutrients.2022;14:4814.879.Epping-JordanJE,PruittSD,BengoaR,etal.Improvingthequalityof
healthcareforchronicconditions.QualSafHealthCare.2004;13:299–305.880.NicollR,RobertsonL,GemmellE,etal.Modelsofcareforchronickidneydisease:asystematicreview.Nephrology(Carlton).2018;23:389–396.881.CollisterD,PyneL,CunninghamJ,etal.Multidisciplinarychronickidneydiseaseclinicpractices:ascopingreview.CanJKidneyHea

---

### Chunk 13/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** results | **Similarity:** 0.567

anginglistof“atrisk”groups.27TestingforCKDwithoutregardtoagegeneratescontro-versy.Thoseinolderagegroupsexperiencethegreatest
burdenofCKDandarealsoatthehighestriskforcardio-
vascularcomplications.Aswithotherdetectionprogramslike
cancerdetection,CKDdetectioneffortsshouldbeindividu-
alizedbasedontheperson’sgoalsofcareandsuitabilityfortreatment.PracticePoint1.1.1.2:Followingincidentaldetectionofelevatedurinaryalbumin-to-creatinineratio(ACR),he-
maturia,orlowestimatedGFR(eGFR),repeatteststo
conrmpresenceofCKD.ThereisknownbiologicalandanalyticalvariabilityinSCrandinurinealbuminorurineproteinnotrelatedtotheir
propertiesasmarkersofkidneydisease.Inpeoplewithout
riskfactorsforCKD,thereisalowpretestprobabilityforCKD.Thus,anyunexpectedresultsshouldbeveriedbeforediagnosingapersonashavingCKD.InpeoplewithriskfactorsforCKD,thereisahigherprobabilitythattheperson
doeshaveCKDevenwithanunexpectednding.Subsequenttestingshouldbeperformedtoconrmthediagnosisandtocompletetheevaluation,asisrequired.Ti

---

### Chunk 14/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** results | **Similarity:** 0.566

tsintheprocessesofdrugstewardshipinpeople
withCKD.Itisbeyondthescopeofthisguidelinetolistall
themedicationsthatmayhavealteredrisks/benetsinpeoplewithCKD.Suchinformationiswidelyavailablein
documentsthatmayexistatlocal,regional,ornationalbodies(e.g.,BritishNationalFormulary:www.bnf.org)andintextbooksofpharmacology.However,wedescribecaseexamplestohighlightthekeyclassesofcommonlypre-
scribedmedicationsinpeoplewithCKD.Thisguidanceis
basedonknowledgeofpharmacologythathasuniversal
relevance.Inmanycases,knowledgeofalteredrisks/benetsofmedicationscomes,however,fromobservationalstudies
andcasereportsfromroutinecare.4.1MedicationchoicesandmonitoringforsafetyAbnormalkidneyfunctionresultsinalterationinpharma-cokineticsandpharmacodynamics,andforpeoplewithCKD,astheGFRworsens,sodoestheprevalenceofpolypharmacy
andcomorbidities.725PeoplewithCKDareatincreasedriskofmedicationerrorsandinappropriateprescribing(noted
tobeupto37%inambulatoryoutpatientstudiesandup
to43%inlong-termcarestudies726,727).Thus,imp

---

### Chunk 15/30
**Article:** Urea levels and cardiovascular disease in patients with chronic kidney disease (2022)
**Journal:** Nephrology Dialysis Transplantation
**Section:** other | **Similarity:** 0.566

20.3(5.1)0%Ageatbaseline(years)69[61–77]68[60–76]69[61–77]69[61–77]0.130%Men,n(%)666566670.710Smoking,n(%)0.030.8Never-smoker,n(%)40.644.539.637.7Currentsmoker,n(%)12.611.711.814.4Formersmoker,n(%)46.843.848.547.9eGFRatbaseline(mL/min/1.73m)33.5(11.6)43.5(9.9)32.6(8.9)24.5(7.0)<0.0010%Albumin-orprotein-to-creatinineratio<0.0018.0A1(normaltomildlyincreased),n(%)28.642.127.016.9A2(moderatelyincreased),n(%)31.831.833.729.7A3(severelyincreased),n(%)39.626.139.253.4Bodymassindex(kg/m)28.8(5.8)28.3(5.2)28.7(5.9)29.5(6.3)<0.0012.0%Diabetes,n(%)44.836.843.953.6<0.0010.2Systolicbloodpressure(mmHg)142(20)142(20)142(21)143(20)0.322.3%Historyofcardiovasculardisease,n(%)53.947.354.659.6<0.0011.3Anaemia,n(%)38.321.135.857.8<0.0010.3Serumbicarbonate(mmol/L)25.0(3.4)25.8(3.1)24.9(3.3)24.1(3.6)<0.0016.9%Serumalbumin(g/L)40.4(4.5)40.6(4.4)40.5(4.2)39.9(4.9)0.00915.2%High-sensitivityC-reactiveprotein(mg/L)2.5[1.1–5.9]2.2[1.1–5.0]2.5[1.1–5.4]2.9[1.2–7.1]<0.00117.6%Historyofacutekidneyinj

---

### Chunk 16/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** introduction | **Similarity:** 0.566

24)105(Suppl4S),S117–S314

SpecialconsiderationsPediatricconsiderations.Newbornswhoclearlyhavekidneydisease(e.g.,severecongenitalmalformationsofthekidneyandurinarytract)donotneedtowait3monthstoconrmCKD.1.1.4EvaluationofcausePracticePoint1.1.4.1:EstablishthecauseofCKDusing
clinicalcontext,personalandfamilyhistory,socialand
environmentalfactors,medications,physicalexamination,
laboratorymeasures,imaging,andgeneticandpathologic
diagnosis(Figure8).PracticePoint1.1.4.2:Useteststoestablishacausebased
onresourcesavailable(Table622,98-100).Inevaluationofcause,healthcareprovidersshouldselectspecicdiagnostictestsbasedonthepretestprobabilityofaspecicdiagnosisinformedbyclinicalpresentation.Identica-tionofcauseconfersbenetfortargetingtherapytoslowpro-gressiontokidneyfailure,understandingcontributingfactors,
andprognosis.Inaddition,identicationofcausecanhelppeoplecommunicateinformationaboutageneticorfamilial
causetorelatives,improveunderstandingoftheirconditioninthecontextofself-caremanageme

---

### Chunk 17/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.562

onsdevelopedforuseinpeoplewithCKDG3–G5,maynotbevalidforuseinthosewithCKDG1–G2.PracticePoint2.2.5:Usedisease-specic,externallyvalidatedpredictionequationsinpeoplewithimmunoglobulinAnephropathy(IgAN)andautosomaldominantpolycystickidneydisease(ADPKD).2.3PredictionofcardiovascularriskinpeoplewithCKDPracticePoint2.3.1:ForcardiovascularriskpredictiontoguidepreventivetherapiesinpeoplewithCKD,useexternallyvalidatedmodelsthatareeitherdevelopedwithinCKDpopulationsorthatincor-porateeGFRandalbuminuria.PracticePoint2.3.2:Formortalityriskpredictiontoguidediscussionsaboutgoalsofcare,useexternallyvalidatedmodelsthatpredictall-causemortalityspecicallydevelopedintheCKDpopulation.Chapter3:DelayingCKDprogressionandmanagingitscomplications3.1CKDtreatmentandriskmodicationPracticePoint3.1.1:TreatpeoplewithCKDwithacomprehensivetreatmentstrategytoreducerisksofprogressionofCKDanditsassociatedcomplications(Figure17).3.2LifestylefactorsPracticePoint3.2.1:EncouragepeoplewithCKDtoundertakephysicalactivitycom

---

### Chunk 18/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.559

anddiabetes:anindividual-participantdatameta-analysisinaGlobalConsortium.Hypertension.2021;78:1042–1052.386.PantaloneKM,JiX,KongSX,etal.Unmetneedsandopportunitiesforoptimalmanagementofpatientswithtype2diabetesandchronickidneydisease.JDiabetesComplications.2023;37:108418.387.KimHS,NgDK,MathesonMB,etal.AssociationofpubertywithchangesinGFRinchildrenwithCKD.AmJKidneyDis.2022;79:131–134.388.GianluigiA,SaraT,ValeriaD,etal.PubertyisassociatedwithincreaseddeteriorationofrenalfunctioninpatientswithCKD:datafromtheItalKidProject.ArchDisChild.2012;97:885–888.389.OshimaM,JardineMJ,AgarwalR,etal.InsightsfromCREDENCEtrialindicateanacutedropinestimatedglomerularltrationrateduringtreatmentwithcanagliozinwithimplicationsforclinicalpractice.KidneyInt.2021;99:999–1009.390.KrausBJ,WeirMR,BakrisGL,etal.Characterizationandimplicationsof
theinitialestimatedglomerularltrationrate’dip’uponsodium-glucosecotransporter-2inhibitionwithempagliozinintheEMPA-REGOUTCOMEtrial.KidneyInt.2021;99:750–762.

---

### Chunk 19/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.558

dneyinjury(AKI)eventoracutekidneydisease(AKD).PracticePoint1.1.3.3:ConsiderinitiationoftreatmentsforCKDatrstpresentationofdecreasedGFRorelevatedACRifCKDisdeemedlikelyduetopresenceofotherclinicalindicators.Kidneydiseasesmaybeacuteorchronic.1,97Weexplicitlyyetarbitrarilydenethedurationofaminimumof3months(>90days)asdelineating“chronic”kidneydisease.TherationalefordeningchronicityistodifferentiateCKDfromAKDs(suchasacuteglomerulonephritis[GN]),includingAKI,whichmayrequiredifferenttimelinesfor
initiationoftreatments,differentinterventions,andhavedifferentetiologiesandoutcomes.Thedurationofkidneydiseasemaybedocumentedorinferredbasedonthe
clinicalcontext.Forexample,apersonwithdecreasedGFR
orkidneydamageduringanacuteillness,withoutprior
documentationofkidneydisease,maybeinferredtohave
AKD.ResolutionoverdaystoweekswouldconrmthediagnosisofAKIfromavarietyofdifferentcauses.A
personwithsimilarndingsintheabsenceofanacuteillnessmaybeinferredtohaveCKD,andiffollowedover
time,wouldbeconrmedtoha

---

### Chunk 20/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.557

.65.05.36.07.01.42.03.04.15.4Ref1.31.92.73.61.01.41.72.43.21.41.72.22.83.82.02.32.83.74.63.23.13.55.06.56.16.46.47.38.2
Figure36|Riskofall-causeandcardiovascularmortalitybyestimatedglomerularltrationrate(eGFR)andlevelofalbuminuriafromgeneralpopulationcohortscontributingtotheChronicKidneyDiseasePrognosisConsortium.ACR,albumin-to-creatinineratio;eGFRcr,creatinine-basedestimatedglomerularltrationrate.ReproducedwithpermissionfromJAMA,WritingGroupfortheCKDPrognosisConsortium;GramsME,CoreshJ,MatsushitaK,etal.Estimatedglomerularltrationrate,albuminuria,andadverseoutcomes:anindividual-participantdatameta-analysis.JAMA.2023;330(13):1266–1277.12Copyrightª2023AmericanMedicalAssociation.Allrightsreserved.

---

### Chunk 21/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** methods | **Similarity:** 0.557

damage†Test for GFR or ACR if not performed and exclude AKI/AKDAKI/AKD present: follow AKI/AKD guidanceGFR <60 ml/min per 1.73 m2 and/orACR ≥30 mg/g [3 mg/mmol] after 3 monthsor earlier if evidence of chronicity
Measure eGFRcr-cys if notperformed and availableCKD not presentTiming of retesting based onindividual characteristics suchas risk of progressionStage according to GFR and ACREstablish underlying causeEstimate risk of progressionInitiate treatmentGFR ≥60 ml/min per 1.73 m2 andACR <30 mg/g [3 mg/mmol]and no other markers ofkidney damage presentGFR <60 ml/min per 1.73 m2 or ACR ≥30 mg/g [3 mg/mmol]and/or other markers of kidney damage present
Figure3|Screeningalgorithmfordiagnosisandstagingofchronickidneydisease(CKD)inadults.RiskfactorconditionsarelistedinTable5.*Forrecommendedmethodstoestimateglomerularltrationrate(eGFR),seeSection1.2.†MarkersofkidneydamageotherthanalbuminuriamayalsobeusedtodiagnoseCKD,butalbumin-to-creatinineratio(ACR)andGFRarestillrequiredtodetermin

---

### Chunk 22/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.556

ta-analysis.ClinJAmSocNephrol.2022;17:1305–1315.193.vanEeghenSA,WiepjesCM,T’SjoenG,etal.CystatinC-basedeGFRchangesduringgender-afrminghormonetherapyintransgenderindividuals.ClinJAmSocNephrol.2023;18:1545–1554.194.PierreC,MarzinkeM,AhmedSB,etal.AACC/NKFguidancedocumenton
improvingequityinchronickidneydiseasecare.JApplLabMed.2023;8:789–816.195.NgDK,FurthSL,WaradyBA,etal.Self-reportedrace,serumcreatinine,
cystatinC,andGFRinchildrenandyoungadultswithpediatrickidney
referenceswww.kidney-international.orgS298KidneyInternational(2024)105(Suppl4S),S117–S314

diseases:areportfromtheChronicKidneyDiseaseinChildren(CKiD)study.AmJKidneyDis.2022;80:174–185.e1.196.Luna-ZaizarH,Virgen-MontelongoM,Cortez-AlvarezCR,etal.Invitro
interferencebyacetaminophen,aspirin,andmetamizoleinserum
measurementsofglucose,urea,andcreatinine.ClinBiochem.2015;48:538–541.197.GreenbergN,RobertsWL,BachmannLM,etal.Specicitycharacteristicsof7commercialcreatininemeasurementproceduresbyenzymaticand
Jaffemethodpri

---

### Chunk 23/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.556

Non-GFRdeterminantsofSCrVegetarianNon-GFRdeterminantsofSCrHigh-proteindietsandcreatinesupplementsNon-GFRdeterminantsofSCrIllnessotherthanCKDMalnutritionChronicillness,presumedimpactonnon-GFR
determinantsofSCrandSCyseGFRcr-cysmaybelessaccuratebecauseofcoexistenceofmalnutritionandinammation.SuggestusingmGFRfortreatmentdecisions
basedonthelevelofGFR.Cancera,132-137Chronicillness,presumedimpactonnon-GFRdeterminantsofSCrandSCyseGFRcr-cysdemonstratedtobemostaccurateinpopulationsstudiedbutlikelihoodoflesser
accuracyinmorefrailpeopleorincancerswithhighcellturnover.SuggestusingmGFRfor
treatmentdecisionsbasedonthelevelofGFR.Heartfailurea,138,139Chronicillness,presumedimpactonnon-GFR
determinantsofSCrandSCysAlthoughlimiteddata,eGFRcysappearslessbiasedbutallhavelowaccuracy.SuggestusingeGFRcr-
cysoreGFRcysforroutineGFRevaluation.Suggest
usingmGFRfortreatmentdecisionsbasedonthe
levelofGFR.Cirrhosisa,79,140,141Chronicillness,presumedimpactonnon-GFR
determinantsofSCrandSCysAlthoughlimiteddata,eGFRcys

---

### Chunk 24/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.556

172.LeveyAS,GreeneT,SchluchterMD,etal.Glomerularltrationratemeasurementsinclinicaltrials.ModicationofDietinRenalDiseaseStudyGroupandtheDiabetesControlandComplicationsTrialResearchGroup.JAmSocNephrol.1993;4:1159–1171.173.PerroneRD,SteinmanTI,BeckGJ,etal.Utilityofradioisotopicltrationmarkersinchronicrenalinsufciency:simultaneouscomparisonof125I-iothalamate,169Yb-DTPA,99mTc-DTPA,andinulin.TheModicationofDietinRenalDiseaseStudy.AmJKidneyDis.1990;16:224–235.174.InkerLA,LeveyAS.KnowingyourGFR-whenisthenumbernot(exactly)
thenumber?KidneyInt.2019;96:280–282.175.ShlipakMG,InkerLA,CoreshJ.SerumcystatinCforestimationofGFR.

---

### Chunk 25/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** results | **Similarity:** 0.555

tagechronickidneydisease:comparativeresultsfromanopen-label,phase3study.NephrolDialTransplant.2021;36:137–150.585.ThinkKidneys,theRenalAssociationandtheBritishSocietyforHeartFailure.ChangesinkidneyfunctionandserumpotassiumduringACE/
ARB/diuretictreatmentinprimarycare.Apositionstatement;2017.

---

### Chunk 26/30
**Article:** 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders (2024)
**Journal:** Archives of Medical Science
**Section:** other | **Similarity:** 0.555

l/min/1.73 m2])Very high Cardiovascular disease documented clinically or by imaging examinations; diabetes mellitus with 
organ damage3 or other major risk factors4,5, early onset type 1 diabetes mellitus lasting > 20 years; chronic kidney disease with eGFR < 30 ml/min/1.73 m2; familial hypercholesterolaemia with cardiovas-cular disease or another major risk factor5; risk ≥ 10% and ≤ 20% according to Pol-SCORE/very high risk according to SCORE2 or SCORE-2-OP for gender and ageHighSigniﬁcantly elevated single risk factor, especially TC > 310 mg/dl (> 8 mmol/l), LDL-C > 190 mg/dl  (> 4.9 mmol/l), or blood pressure ≥ 180/110 mm Hg; familial hypercholesterolaemia without other risk factors; diabetes mellitus without organ damage (regardless of duration)6; chronic kidney disease with eGFR 3059 ml/min/1.73 m2; risk ≥ 5% and < 10% according to Pol-SCORE /high risk according to SCORE2 or SCORE-2-OP for gender and ageModerateRisk < 5% according to Pol-SCORE/low and moderate risk acc

---

### Chunk 27/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** results | **Similarity:** 0.553

tNZJMed.1992;22:334–337.338.GilbertRE,AkdenizA,JerumsG.Detectionofmicroalbuminuriaindiabeticpatientsbyurinarydipstick.DiabetesResClinPract.1997;35:57–60.339.GrazianiMS,GambaroG,MantovaniL,etal.Diagnosticaccuracyofa
reagentstripforassessingurinaryalbuminexcretioninthegeneralpopulation.NephrolDialTransplant.2008;24:1490–1494.340.GuyM,NewallR,BorzomatoJ,etal.Useofarst-lineurineprotein-to-creatinineratiostriptestonrandomurinestoruleoutproteinuriain
patientswithchronickidneydisease.NephrolDialTransplant.2008;24:1189–1193.341.GuyM,NewallR,BorzomatoJ,etal.Diagnosticaccuracyoftheurinary
albumin:creatinineratiodeterminedbytheCLINITEKMicroalbuminandDCA2000þfortherule-outofalbuminuriainchronickidneydisease.ClinChimActa.2008;399:54–58.342.HasslacherC,MullerP,SchlipfenbacherRL.ResultsofamulticentrestudyforthedeterminationofmicroalbuminuriawithMicral-Test.KlinischesLabor.1995;41:441–447.343.HodelNC,HamadA,ReitherK,etal.Comparisonoftwodifferent
semiquantitativeurinarydipsticktestswithal

---

### Chunk 28/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.553

DG5disease.Giventhegreaterriskofdiseaseprogression,thosewithhigherriskofdisease
progressionshouldundergomorefrequentmonitoring
(Figure1329).Morefrequentmonitoringmaybeindicatedinpeoplewithchangingclinicalstatus,intercurrentevents,and
aftertherapeuticinterventionstoassessresponseand
adherenceandensuresafety.Inaddition,progressionrisk
mayvarybytheetiologyofCKDwithinaspecicstagebasedonGFRandalbuminuriaorproteinuria.PracticePoint2.1.3:ForpeoplewithCKD,achangeineGFRof>20%onasubsequenttestexceedstheexpectedvariabilityandwarrantsevaluation.Within-subjectvariationinmeasuredandeGFRiswelldescribed(Figure12).Thus,theabilitytodistinguishbetweenbiologicalandanalyticalversuspathologicalvariationinthe
mGFRandeGFRisimportantforhealthcareprovidersandpeoplewithCKD.StudiesshowthatintraindividualbiologicalvariationineGFRissimilaracrosseGFR
equations:CKD-EPI-creatinine(5.3%[4.5%–6.4%]),CKD-EPI-cystatinC(5.3%[4.5%–6.5%]),andCKD-EPI-creatinine-cystatinC(5.0%[4.3%–6.2%]).Thereferencechangevalue(RCV)isd

---

### Chunk 29/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** results | **Similarity:** 0.552

k forrecurrence afterkidney transplantationConditions for whichgenetic testing isrelevant for reproductivecounselingExamples:• GLA (Fabry)• AGXT (primaryhyperoxaluria (PH))• CoQ10 genes (SRNS)• CTNS (cystinosis)• Tubulopathies(Na+, K+ etc.)Conditions amenable to nonspecific renoprotective strategiesExample:• COL4A3/4/5 (Alport)and RAAS blockadeExample:
• Glomerular diseasedue to mutations inAlport genes(COL4A3/4/5)Examples:• (CFH/CFI/C3...): aHUS• (AGXT, GRHPR, HOGA): primary hyperoxaluria (PH)
• Adenine phosphoribo-  syltransferase deficiency (APRT)Conditions amenable to specific screening for extrarenal manifestationsExamples:• HNF1B: diabetes• PKD1/PKD2(ADPKD): intracranialaneurysms • FLCN: renal cellcarcinoma, etc.Example:
• Prenatal/preimplantationdiagnosis
Figure9|Actionablegenesinkidneydisease.Actionabilityreferstothepotentialforgeneticrestresultstoleadtospecicclinicalactionsfrompreventionortreatmentofacondition,supportedbyrecommendationsbasedonevide

---

### Chunk 30/30
**Article:** Fisiologia e Bioquímica do Sistema Imune II (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.551

olicitar e registrar parâmetros essenciais (PCR-us, VHS); calcular índices estimáveis (HGI, TAIG); considerar complementares (TNF-α, IL-6, GPx, MDA, antioxidantes totais).
- [ ] 11. Monitorar trimestralmente HbA1c, glicemia de jejum e HGI; estabelecer metas individuais (ex.: reduzir de 6,1 para ~5,5; longo prazo ~5,3).
- [ ] 12. Calcular TG/HDL e integrar com lipidograma/SREBP1c/2; evitar combinação de gordura saturada com açúcar e excesso de saturadas em múltiplas refeições.
- [ ] 13. Avaliar ferro, ferritina, transferrina e saturação (20–50%; evitar <20%); interpretar com hepcidina/SREBP1c e quadro inflamatório.
- [ ] 14. Medir TNF-α (<8,1) e IL-6 (<3,4) para acompanhar atividade inflamatória; relacionar com obesidade inflamada.
- [ ] 15. Calcular HOMA-β (167–175) e HOMA-IR (<2,15); buscar glicemia 60–90 e insulina ~6–7.
- [ ] 16. Monitorar homocisteína (<7,9) e PCR; usar PCR-us; documentar crises (PCR >1.000) e conduzir manejo apropriado.
- [ ] 17.

---

